328 related articles for article (PubMed ID: 26973098)
21. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and in vitro and in vivo evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography.
Lindner S; Michler C; Leidner S; Rensch C; Wängler C; Schirrmacher R; Bartenstein P; Wängler B
Bioconjug Chem; 2014 Apr; 25(4):738-49. PubMed ID: 24666287
[TBL] [Abstract][Full Text] [Related]
23. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging.
Liu Z; Niu G; Wang F; Chen X
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1483-94. PubMed ID: 19360404
[TBL] [Abstract][Full Text] [Related]
24.
Rinne SS; Abouzayed A; Gagnon K; Tolmachev V; Orlova A
Sci Rep; 2021 Feb; 11(1):3631. PubMed ID: 33574368
[TBL] [Abstract][Full Text] [Related]
25. In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.
Marsouvanidis PJ; Melis M; de Blois E; Breeman WA; Krenning EP; Maina T; Nock BA; de Jong M
Cancer Biother Radiopharm; 2014 Nov; 29(9):359-67. PubMed ID: 25286347
[TBL] [Abstract][Full Text] [Related]
26. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
[TBL] [Abstract][Full Text] [Related]
27. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
Brand C; Longo VA; Groaning M; Weber WA; Reiner T
Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
[TBL] [Abstract][Full Text] [Related]
28. 44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?
Koumarianou E; Loktionova NS; Fellner M; Roesch F; Thews O; Pawlak D; Archimandritis SC; Mikolajczak R
Appl Radiat Isot; 2012 Dec; 70(12):2669-76. PubMed ID: 23037921
[TBL] [Abstract][Full Text] [Related]
29. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
[TBL] [Abstract][Full Text] [Related]
30. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of
Liu Q; Cai S; Ye J; Xie Q; Liu R; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1826-1840. PubMed ID: 38319321
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides.
Mansi R; Wang X; Forrer F; Kneifel S; Tamma ML; Waser B; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2009 Aug; 15(16):5240-9. PubMed ID: 19671861
[TBL] [Abstract][Full Text] [Related]
33. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
Schuhmacher J; Zhang H; Doll J; Mäcke HR; Matys R; Hauser H; Henze M; Haberkorn U; Eisenhut M
J Nucl Med; 2005 Apr; 46(4):691-9. PubMed ID: 15809493
[TBL] [Abstract][Full Text] [Related]
34. A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor-Positive Prostate Cancer.
Bratanovic IJ; Zhang C; Zhang Z; Kuo HT; Colpo N; Zeisler J; Merkens H; Uribe C; Lin KS; Bénard F
J Nucl Med; 2022 Mar; 63(3):424-430. PubMed ID: 34301778
[TBL] [Abstract][Full Text] [Related]
35. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
[TBL] [Abstract][Full Text] [Related]
36. Taking cyclotron
Nelson BJB; Wilson J; Richter S; Duke MJM; Wuest M; Wuest F
Nucl Med Biol; 2020; 80-81():24-31. PubMed ID: 32004935
[TBL] [Abstract][Full Text] [Related]
37. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
[TBL] [Abstract][Full Text] [Related]
38. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent
Schreck MV; Burgard C; Schmidtke A; Hierlmeier I; Stemler T; Maus S; Rosar F; Jung M; Speicher A; Ezziddin S; Holland JP; Bartholomä MD
Mol Pharm; 2023 Dec; 20(12):6463-6473. PubMed ID: 37978936
[TBL] [Abstract][Full Text] [Related]
39.
Hajiramezanali M; Atyabi F; Mosayebnia M; Akhlaghi M; Geramifar P; Jalilian AR; Mazidi SM; Yousefnia H; Shahhosseini S; Beiki D
Int J Nanomedicine; 2019; 14():2591-2605. PubMed ID: 31040674
[TBL] [Abstract][Full Text] [Related]
40. The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.
Varasteh Z; Rosenström U; Velikyan I; Mitran B; Altai M; Honarvar H; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Molecules; 2014 Jul; 19(7):10455-72. PubMed ID: 25036155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]